US BIOTECH PHASE II/III SHORTLIST
Which CRO fits your Phase II/III clinical trial?
Compare published phase coverage, therapeutic focus, and delivery models across 16 shortlisted CROs before sending an RFI. Study pricing was not established from reviewed service pages and must be requested per study.
| CRO | Phase scope | Therapeutic focus | Delivery model |
|---|---|---|---|
IQVIA | Phase IIb/III TrialsVendor service page claim; this title establishes a marketed Phase IIb/III offering only, not study-specific experience, performance or suitability.Source ↗ · Record | Includes oncology/hematology, CNS, rare disease, obesity and cell/gene therapy.Company-wide claim; ask for matching study references and a named available team.Source & date | Not detailed on reviewed page Why unknown |
ICON plc | Phase 2–3 clinical operationsCompany-wide claim; ask for matching study references and a named available team.Source & date | Cardio-metabolic, oncology/hematology, infection, neurology/psychiatry, rare disease, respiratory and biosimilars.Company-wide claim; ask for matching study references and a named available team.Source & date | Traditional, decentralized or hybrid trial deliveryCompany-wide claim; ask for matching study references and a named available team.Source & date |
Medpace | all phases of development (including wholly-owned Phase I Unit)Vendor homepage claim; does not establish indication-specific trial counts or study outcomes.Source ↗ · Record | Includes oncology/hematology, endocrine/metabolic, neuroscience, immunology and rare disease.Company-wide claim; ask for matching study references and a named available team.Source & date | full-service, single-vendor outsourcing with wholly-owned Central Labs, Bioanalytical Lab, Imaging Core Lab, ECG Core Lab and CTMSVendor-stated full-service model; FSP availability not offered/stated on homepage.Source ↗ · Record |
Parexel | Phase IIb-IV clinical trialsSource ↗ · Record | General medicine, infectious disease and vaccines, immunology, neuroscienceVendor-listed therapeutic areas on integrated clinical development page; additional therapeutic areas may appear on separate pages.Source ↗ · Record | Integrated clinical development with Site Alliance Network, decentralized trial (DCT) elements, regulatory strategy, clinical logistics, pharmacovigilanceVendor service statement; protocol-level site availability requires verification.Source ↗ · Record |
Syneos Health | all phases including Early Phase, Phase II-IV and Real World EvidenceSource ↗ · Record | oncology and hematology, neuroscience, rare disease, dermatologyVendor claim; self-reported ~70% biotech customer portfolio.Source ↗ · Record | Full-service outsourcing (FSO) and Functional Service Provider (FSP 360)Source ↗ · Record |
Fortrea | Not stated on reviewed page Why unknown | Not listed on reviewed page Why unknown | full service and FSP clinical development with FDA Diversity Action Plan supportVendor service statement; does not specify individual trial phase exclusions.Source ↗ · Record |
Thermo Fisher Scientific, PPD clinical services | early development, all phases of clinical development, peri- and post-approvalSource ↗ · Record | Not listed on reviewed page Why unknown | full-service partnerships, functional service partnerships (FSP), and comprehensive laboratory servicesSource ↗ · Record |
Labcorp Drug Development | Not stated on reviewed page Why unknown | Not listed on reviewed page Why unknown | nonclinical development, central lab services (100+ countries), and companion diagnostics (distinct lab/enablement focus)Current biopharma page foregrounds laboratory, nonclinical, and CDx services rather than standalone full-service CRO trial management.Source ↗ · Record |
Worldwide Clinical Trials | Phase I-IIa, Phase II-IV (specializing in Phase IIb-IV peri-approval), RWE, and Transition StudiesVendor capability claim; specific therapeutic indications sit on separate subpages.Source ↗ · Record | Not listed on reviewed page Why unknown | Phase I-IV trial execution, RWE, and Transition Studies (mid-trial rescue)Vendor markets mid-trial transition/rescue capability.Source ↗ · Record |
Precision for Medicine | Early Phase (first-in-human through Phase 2a) and Late Phase (Phase 2b-4 pivotal)Source ↗ · Record | Oncology & immuno-oncology (stated 76% of trials), rare & orphan diseases (stated 67% of trials), autoimmune, cell/gene therapyVendor self-reported trial percentages; percentages overlap because trials can be both oncology and rare disease.Source ↗ · Record | Full-service CRO and FSP services with integrated translational/biomarker science and Precision labsSource ↗ · Record |
Veristat | complex Phase I-III clinical developmentSource ↗ · Record | rare disease trial delivery and complex specialty programsVendor lists rare disease and natural history trial delivery; other indications not enumerated on page.Source ↗ · Record | specialty CRO combining regulatory advisory, biostatistics/InStat, clinical operations, DCT, and clinical trial rescueSource ↗ · Record |
Premier Research | Not stated on reviewed page Why unknown | Not listed on reviewed page Why unknown | global full-service CRO with clinical research and consulting across the development lifecycleHomepage statement only; therapeutic areas and specific trial phases sit on linked subpages not captured here.Source ↗ · Record |
Indero | early and late phase clinical trialsSource ↗ · Record | dual-focus dermatology (30+ indications) and rheumatology (20+ indications)Specialty dual-focus CRO; North America CRU operates as Innovaderm.Source ↗ · Record | dual-focus specialty CRO (formerly Innovaderm) with affiliated clinical research unit for North America/global trialsHeadquartered in Montreal, Canada with North America trial capabilities.Source ↗ · Record |
Kapadi | Not stated on reviewed page Why unknown | oncology (solid and liquid malignancies, immuno-oncology) and cell & gene therapies (common and rare indications)Vendor specialty positioning; notes partnership/historic connection to Moffitt Cancer Center.Source ↗ · Record | global full service and FSP oncology/CGT CROVendor service statement; specific trial phases not enumerated on homepage.Source ↗ · Record |
PharPoint | Phase II-IV clinical trialsSource ↗ · Record | Not listed on reviewed page Why unknown | Full-service Phase II-IV CRO covering site feasibility, clinical operations, data management, and biostatisticsVendor service statement; notes APAC CRO partner network alongside US work.Source ↗ · Record |
Proxima CRO | Not stated on reviewed page Why unknown | Not listed on reviewed page Why unknown | Biotech and MedTech CRO covering drugs, medical devices, and diagnostics (regulatory strategy, quality systems, clinical trials, RWE)Mixed MedTech and biotech scope; confirm pure-biotech Phase II/III drug trial depth separately.Source ↗ · Record |